Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NLR family pyrin domain containing 3 (NLRP3) inflammasome complex is a multi-protein intracellular signaling platform that plays a pivotal role in the innate immune system's response to infection and cellular stress [PMID: 31034466]. It consists of the NLRP3 sensor protein, the adapter protein ASC (apoptosis-associated speck-like protein containing a CARD), and the effector enzyme pro-caspase-1 [UniProt: Q96P20]. Upon activation by a diverse array of stimuli—including extracellular ATP, crystalline particles like uric acid, and pore-forming toxins—the complex assembles to trigger the maturation of pro-inflammatory cytokines interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) [StatPearls: Inflammasome]. This process also leads to pyroptosis, a form of programmed inflammatory cell death that further amplifies the immune response [PMID: 27951526]. Chronic or excessive activation of this pathway is a major driver of various inflammatory pathologies, ranging from rare autoinflammatory syndromes like Cryopyrin-Associated Periodic Syndromes (CAPS) to common metabolic and neurodegenerative diseases [PMID: 33035211]. Therapeutic strategies targeting the NLRP3 inflammasome focus on small-molecule inhibitors that prevent its assembly or activation, offering a promising approach to treating systemic inflammation [PMID: 31034466]. Several inhibitors, such as Dapansutrile, are currently in clinical trials for conditions like gout and heart failure [ClinicalTrials.gov: NCT03034486]. By specifically targeting the NLRP3 sensor, these drugs aim to provide potent anti-inflammatory effects while minimizing the broad immunosuppression associated with upstream cytokine blockers.
Inhibition of the NLRP3 ATPase activity, prevention of NLRP3 oligomerization, or blocking the recruitment of the ASC adapter protein, thereby preventing the activation of caspase-1 and the subsequent release of IL-1β and IL-18 [PMID: 31034466].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NLR family pyrin domain containing 3 (NLRP3) inflammasome complex (NLRP3 inflammasome).